Do analysts rate SNGX or TCRX?

TScan Therapeutics has a consensus price target of $2.67, indicating a potential upside of 863.04%. Given TScan Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe TScan Therapeutics is more favorable than Soligenix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Soligenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 TScan Therapeutics 1 Sell rating(s) 5 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.13

Does the media refer more to SNGX or TCRX?

In the previous week, TScan Therapeutics had 1 more articles in the media than Soligenix. MarketBeat recorded 2 mentions for TScan Therapeutics and 1 mentions for Soligenix. Soligenix's average media sentiment score of 0.00 equaled TScan Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Soligenix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral TScan Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer SNGX or JSPR?

Jasper Therapeutics has a consensus price target of $7.33, indicating a potential upside of 1,187.23%. Given Jasper Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Jasper Therapeutics is more favorable than Soligenix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Soligenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Jasper Therapeutics 1 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.29

Is SNGX or JSPR more profitable?

Soligenix's return on equity of -180.25% beat Jasper Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Soligenix N/A -180.25% -107.46% Jasper Therapeutics N/A -884.17% -143.83%

Does the media refer more to SNGX or JSPR?

In the previous week, Jasper Therapeutics had 1 more articles in the media than Soligenix. MarketBeat recorded 2 mentions for Jasper Therapeutics and 1 mentions for Soligenix. Jasper Therapeutics' average media sentiment score of 0.29 beat Soligenix's score of 0.00 indicating that Jasper Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Soligenix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Jasper Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend ESLA or SNGX?

Estrella Immunopharma presently has a consensus target price of $8.00, suggesting a potential upside of 1,804.76%. Given Estrella Immunopharma's stronger consensus rating and higher possible upside, research analysts plainly believe Estrella Immunopharma is more favorable than Soligenix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Estrella Immunopharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Soligenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ESLA or SNGX more profitable?

Estrella Immunopharma's return on equity of 0.00% beat Soligenix's return on equity. Company Net Margins Return on Equity Return on Assets Estrella Immunopharma N/A N/A -328.72% Soligenix N/A -180.25% -107.46%

Does the media prefer ESLA or SNGX?

In the previous week, Estrella Immunopharma had 1 more articles in the media than Soligenix. MarketBeat recorded 2 mentions for Estrella Immunopharma and 1 mentions for Soligenix. Estrella Immunopharma's average media sentiment score of 0.79 beat Soligenix's score of 0.00 indicating that Estrella Immunopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Estrella Immunopharma 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Soligenix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend SNGX or ATOS?

Atossa Genetics has a consensus target price of $20.33, indicating a potential upside of 726.56%. Given Atossa Genetics' stronger consensus rating and higher probable upside, analysts clearly believe Atossa Genetics is more favorable than Soligenix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Soligenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Atossa Genetics 2 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.20

Is SNGX or ATOS more profitable?

Atossa Genetics' return on equity of -102.99% beat Soligenix's return on equity. Company Net Margins Return on Equity Return on Assets Soligenix N/A -180.25% -107.46% Atossa Genetics N/A -102.99% -85.78%

Does the media refer more to SNGX or ATOS?

In the previous week, Atossa Genetics had 9 more articles in the media than Soligenix. MarketBeat recorded 10 mentions for Atossa Genetics and 1 mentions for Soligenix. Atossa Genetics' average media sentiment score of 0.73 beat Soligenix's score of 0.00 indicating that Atossa Genetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Soligenix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Atossa Genetics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer SNGX or NEUP?

Neuphoria Therapeutics has a consensus price target of $7.00, indicating a potential upside of 104.68%. Given Neuphoria Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Neuphoria Therapeutics is more favorable than Soligenix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Soligenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Neuphoria Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Is SNGX or NEUP more profitable?

Neuphoria Therapeutics' return on equity of -38.31% beat Soligenix's return on equity. Company Net Margins Return on Equity Return on Assets Soligenix N/A -180.25% -107.46% Neuphoria Therapeutics N/A -38.31% -28.92%

Soligenix (SNGX) Competitors

$0.35 0.00 (-0.14%)

As of 11:51 AM Eastern

Compare

SNGX vs. TCRX, JSPR, ESLA, ATOS, and NEUP

Should you buy Soligenix stock or one of its competitors? Soligenix's main competitors and comparable companies include TScan Therapeutics (TCRX), Jasper Therapeutics (JSPR), Estrella Immunopharma (ESLA), Atossa Genetics (ATOS), and Neuphoria Therapeutics (NEUP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Soligenix compare to TScan Therapeutics?

Soligenix (NASDAQ:SNGX) and TScan Therapeutics (NASDAQ:TCRX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, media sentiment, risk, earnings and profitability.

Soligenix has higher earnings, but lower revenue than TScan Therapeutics. Soligenix is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Soligenix	$120K	43.66	-$11.08M	-$0.98	N/A
TScan Therapeutics	$10.32M	1.82	-$129.77M	-$0.91	N/A

TScan Therapeutics has a consensus price target of $2.67, indicating a potential upside of 863.04%. Given TScan Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe TScan Therapeutics is more favorable than Soligenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Soligenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
TScan Therapeutics	1 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.13

Soligenix has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,655.35%. TScan Therapeutics' return on equity of -108.72% beat Soligenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Soligenix	N/A	-180.25%	-107.46%
TScan Therapeutics	-1,655.35%	-108.72%	-54.47%

In the previous week, TScan Therapeutics had 1 more articles in the media than Soligenix. MarketBeat recorded 2 mentions for TScan Therapeutics and 1 mentions for Soligenix. Soligenix's average media sentiment score of 0.00 equaled TScan Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Soligenix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
TScan Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Soligenix has a beta of 1.99, indicating that its stock price is 99% more volatile than the broader market. Comparatively, TScan Therapeutics has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market.

3.6% of Soligenix shares are held by institutional investors. Comparatively, 82.8% of TScan Therapeutics shares are held by institutional investors. 1.9% of Soligenix shares are held by company insiders. Comparatively, 6.3% of TScan Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

TScan Therapeutics beats Soligenix on 11 of the 15 factors compared between the two stocks.

How does Soligenix compare to Jasper Therapeutics?

Soligenix (NASDAQ:SNGX) and Jasper Therapeutics (NASDAQ:JSPR) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, media sentiment, profitability, earnings, valuation, dividends and analyst recommendations.

3.6% of Soligenix shares are owned by institutional investors. Comparatively, 79.9% of Jasper Therapeutics shares are owned by institutional investors. 1.9% of Soligenix shares are owned by insiders. Comparatively, 3.9% of Jasper Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Soligenix's return on equity of -180.25% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Soligenix	N/A	-180.25%	-107.46%
Jasper Therapeutics	N/A	-884.17%	-143.83%

In the previous week, Jasper Therapeutics had 1 more articles in the media than Soligenix. MarketBeat recorded 2 mentions for Jasper Therapeutics and 1 mentions for Soligenix. Jasper Therapeutics' average media sentiment score of 0.29 beat Soligenix's score of 0.00 indicating that Jasper Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Soligenix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Jasper Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Soligenix has a beta of 1.99, suggesting that its stock price is 99% more volatile than the broader market. Comparatively, Jasper Therapeutics has a beta of 3.16, suggesting that its stock price is 216% more volatile than the broader market.

Jasper Therapeutics has a consensus price target of $7.33, indicating a potential upside of 1,187.23%. Given Jasper Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Jasper Therapeutics is more favorable than Soligenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Soligenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

Soligenix has higher revenue and earnings than Jasper Therapeutics. Soligenix is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Soligenix	$120K	43.66	-$11.08M	-$0.98	N/A
Jasper Therapeutics	N/A	N/A	-$75.80M	-$1.59	N/A

Summary

Jasper Therapeutics beats Soligenix on 9 of the 14 factors compared between the two stocks.

How does Soligenix compare to Estrella Immunopharma?

Estrella Immunopharma (NASDAQ:ESLA) and Soligenix (NASDAQ:SNGX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations and earnings.

Estrella Immunopharma's return on equity of 0.00% beat Soligenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Estrella Immunopharma	N/A	N/A	-328.72%
Soligenix	N/A	-180.25%	-107.46%

Estrella Immunopharma has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market. Comparatively, Soligenix has a beta of 1.99, indicating that its stock price is 99% more volatile than the broader market.

0.4% of Estrella Immunopharma shares are owned by institutional investors. Comparatively, 3.6% of Soligenix shares are owned by institutional investors. 5.8% of Estrella Immunopharma shares are owned by company insiders. Comparatively, 1.9% of Soligenix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Estrella Immunopharma presently has a consensus target price of $8.00, suggesting a potential upside of 1,804.76%. Given Estrella Immunopharma's stronger consensus rating and higher possible upside, research analysts plainly believe Estrella Immunopharma is more favorable than Soligenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Soligenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Soligenix has higher revenue and earnings than Estrella Immunopharma. Estrella Immunopharma is trading at a lower price-to-earnings ratio than Soligenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.24	N/A
Soligenix	$120K	43.66	-$11.08M	-$0.98	N/A

In the previous week, Estrella Immunopharma had 1 more articles in the media than Soligenix. MarketBeat recorded 2 mentions for Estrella Immunopharma and 1 mentions for Soligenix. Estrella Immunopharma's average media sentiment score of 0.79 beat Soligenix's score of 0.00 indicating that Estrella Immunopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Estrella Immunopharma	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Soligenix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Estrella Immunopharma beats Soligenix on 8 of the 14 factors compared between the two stocks.

How does Soligenix compare to Atossa Genetics?

Soligenix (NASDAQ:SNGX) and Atossa Genetics (NASDAQ:ATOS) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations and media sentiment.

In the previous week, Atossa Genetics had 9 more articles in the media than Soligenix. MarketBeat recorded 10 mentions for Atossa Genetics and 1 mentions for Soligenix. Atossa Genetics' average media sentiment score of 0.73 beat Soligenix's score of 0.00 indicating that Atossa Genetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Soligenix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Atossa Genetics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Soligenix has a beta of 1.99, meaning that its stock price is 99% more volatile than the broader market. Comparatively, Atossa Genetics has a beta of 1.27, meaning that its stock price is 27% more volatile than the broader market.

Atossa Genetics' return on equity of -102.99% beat Soligenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Soligenix	N/A	-180.25%	-107.46%
Atossa Genetics	N/A	-102.99%	-85.78%

Soligenix has higher revenue and earnings than Atossa Genetics. Atossa Genetics is trading at a lower price-to-earnings ratio than Soligenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Soligenix	$120K	43.66	-$11.08M	-$0.98	N/A
Atossa Genetics	N/A	N/A	-$34.77M	-$3.11	N/A

3.6% of Soligenix shares are owned by institutional investors. Comparatively, 12.7% of Atossa Genetics shares are owned by institutional investors. 1.9% of Soligenix shares are owned by insiders. Comparatively, 9.8% of Atossa Genetics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Atossa Genetics has a consensus target price of $20.33, indicating a potential upside of 726.56%. Given Atossa Genetics' stronger consensus rating and higher probable upside, analysts clearly believe Atossa Genetics is more favorable than Soligenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Soligenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Atossa Genetics beats Soligenix on 9 of the 14 factors compared between the two stocks.

How does Soligenix compare to Neuphoria Therapeutics?

Soligenix (NASDAQ:SNGX) and Neuphoria Therapeutics (NASDAQ:NEUP) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings.

Soligenix has a beta of 1.99, meaning that its share price is 99% more volatile than the broader market. Comparatively, Neuphoria Therapeutics has a beta of 0.75, meaning that its share price is 25% less volatile than the broader market.

3.6% of Soligenix shares are owned by institutional investors. Comparatively, 15.9% of Neuphoria Therapeutics shares are owned by institutional investors. 1.9% of Soligenix shares are owned by company insiders. Comparatively, 1.6% of Neuphoria Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Soligenix had 1 more articles in the media than Neuphoria Therapeutics. MarketBeat recorded 1 mentions for Soligenix and 0 mentions for Neuphoria Therapeutics. Soligenix's average media sentiment score of 0.00 equaled Neuphoria Therapeutics'average media sentiment score.

Company	Overall Sentiment
Soligenix	Neutral
Neuphoria Therapeutics	Neutral

Neuphoria Therapeutics' return on equity of -38.31% beat Soligenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Soligenix	N/A	-180.25%	-107.46%
Neuphoria Therapeutics	N/A	-38.31%	-28.92%

Neuphoria Therapeutics has a consensus price target of $7.00, indicating a potential upside of 104.68%. Given Neuphoria Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Neuphoria Therapeutics is more favorable than Soligenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Soligenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Neuphoria Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Soligenix has higher earnings, but lower revenue than Neuphoria Therapeutics. Neuphoria Therapeutics is trading at a lower price-to-earnings ratio than Soligenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Soligenix	$120K	43.66	-$11.08M	-$0.98	N/A
Neuphoria Therapeutics	$1.17M	15.81	-$13.45M	-$6.22	N/A

Summary

Soligenix beats Neuphoria Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Soligenix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SNGX vs. The Competition

Export

Metric	Soligenix	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.23M	$3.76B	$7.06B	$13.32B
Dividend Yield	N/A	3.66%	2.53%	16.47%
P/E Ratio	-0.36	13.50	274.97	25.99
Price / Sales	43.60	1,180.99	573.57	85.51
Price / Cash	N/A	118.37	77.41	52.81
Price / Book	0.68	16.00	10.74	6.20
Net Income	-$11.08M	-$22.65M	$3.50B	$382.01M
7 Day Performance	-2.97%	-4.32%	-2.44%	-1.42%
1 Month Performance	-6.59%	-13.49%	-7.90%	-5.62%
1 Year Performance	-80.50%	7.61%	2.26%	-1.74%

Soligenix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SNGX Soligenix	0.552 of 5 stars	$0.35 -0.1%	N/A	-78.4%	$5.23M	$120K	N/A	14
TCRX TScan Therapeutics	2.7505 of 5 stars	$0.32 -6.6%	$2.67 +739.9%	-85.9%	$21.52M	$10.32M	N/A	142	Gap Down
JSPR Jasper Therapeutics	1.6792 of 5 stars	$0.63 -0.1%	$7.33 +1,072.6%	-76.6%	$20.81M	N/A	N/A	22	News Coverage
ESLA Estrella Immunopharma	1.6929 of 5 stars	$0.46 +6.7%	$8.00 +1,638.8%	-66.7%	$20.01M	N/A	N/A	N/A	News Coverage Gap Down
ATOS Atossa Genetics	2.3092 of 5 stars	$1.99 +1.5%	$20.33 +921.8%	-83.8%	$19.86M	N/A	N/A	14	Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SNGX) was last updated on 10/8/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Soligenix (SNGX) Competitors

SNGX vs. TCRX, JSPR, ESLA, ATOS, and NEUP

How does Soligenix compare to TScan Therapeutics?

Summary

How does Soligenix compare to Jasper Therapeutics?

Summary

How does Soligenix compare to Estrella Immunopharma?

Summary

How does Soligenix compare to Atossa Genetics?

Summary

How does Soligenix compare to Neuphoria Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNGX vs. The Competition

Soligenix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Soligenix (SNGX) Competitors

SNGX vs. TCRX, JSPR, ESLA, ATOS, and NEUP

How does Soligenix compare to TScan Therapeutics?

Which has preferable valuation and earnings, SNGX or TCRX?

Do analysts rate SNGX or TCRX?

Is SNGX or TCRX more profitable?

Does the media refer more to SNGX or TCRX?

Which has more volatility and risk, SNGX or TCRX?

Do institutionals and insiders have more ownership in SNGX or TCRX?

Summary

How does Soligenix compare to Jasper Therapeutics?

Do insiders & institutionals believe in SNGX or JSPR?

Is SNGX or JSPR more profitable?

Does the media refer more to SNGX or JSPR?

Which has more risk & volatility, SNGX or JSPR?

Do analysts prefer SNGX or JSPR?

Which has better valuation and earnings, SNGX or JSPR?

Summary

How does Soligenix compare to Estrella Immunopharma?

Is ESLA or SNGX more profitable?

Which has more volatility & risk, ESLA or SNGX?

Do insiders & institutionals hold more shares of ESLA or SNGX?

Do analysts recommend ESLA or SNGX?

Which has stronger valuation and earnings, ESLA or SNGX?

Does the media prefer ESLA or SNGX?

Summary

How does Soligenix compare to Atossa Genetics?

Does the media refer more to SNGX or ATOS?

Which has more risk & volatility, SNGX or ATOS?

Is SNGX or ATOS more profitable?

Which has stronger earnings and valuation, SNGX or ATOS?

Do insiders and institutionals believe in SNGX or ATOS?

Do analysts recommend SNGX or ATOS?

Summary

How does Soligenix compare to Neuphoria Therapeutics?

Which has more volatility & risk, SNGX or NEUP?

Do insiders & institutionals believe in SNGX or NEUP?

Does the media prefer SNGX or NEUP?

Is SNGX or NEUP more profitable?

Do analysts prefer SNGX or NEUP?

Which has higher valuation and earnings, SNGX or NEUP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNGX vs. The Competition

Soligenix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools